Pharma player Zydus Cadila on Saturday announced that the patent litigation relating to Allergan's Delzicol (mesalamine) has been settled.
The settlement, subject to the approval from the regulator, will open the doors for the company to market its generic version in the US market.
"As a result of the settlement, and if approved by FDA, company's US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of Delzicol in the United States beginning on March 1, 2020, or earlier under certain circumstances," the company informed in a statement here.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.